Oncolytics Biotech (ONCY) Net Income towards Common Stockholders (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$10.8 million in Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 55.2% year-over-year to -$10.8 million in Q3 2025; TTM through Dec 2025 was -$15.6 million, a 12.64% increase from a year earlier, with the FY2025 full-year figure at -$28.8 million, down 25.2% from the prior year.
• Net Income towards Common Stockholders for Q3 2025 stood at -$10.8 million, down from -$4.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ONCY reached as high as $7.3 million in Q3 2023 and fell as low as -$35.6 million in Q4 2021.
• Historically, Net Income towards Common Stockholders has averaged -$5.6 million across 5 years, with a median of -$4.8 million in 2025.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 331.24% in 2023 and fell as far as 242.15% in 2023.
• Year by year, Net Income towards Common Stockholders stood at -$35.6 million in 2021, then increased by 15.98% to -$29.9 million in 2022, then soared by 90.67% to -$2.8 million in 2023, then slumped by 104.32% to -$5.7 million in 2024, then tumbled by 89.8% to -$10.8 million in 2025.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$10.8 million in Q3 2025, -$4.8 million in Q2 2025, and -$5.7 million in Q4 2024.